In a previous study, we demonstrated that bufalin caused apoptosis in human leukemia U937 cells by the anomalous activation of mitogen-activated protein kinase (MAPK) via a signaling pathway that included Ras, Raf-1 and MAPK kinase-1. We report here the eect of bufalin on c-Jun N-terminal protein kinase (JNK), a member of the MAPK family, and on the signaling pathway downstream of MAPKs in U937 cells. When U937 cells were treated with 10 78 M bufalin, the activity of JNK1 was markedly elevated 3 h after the start of treatment and remained so for 9 h. This activation of JNK and the induction of apoptosis by bufalin were suppressed by expression of antisense mRNA for MAPK kinase-1. c-Jun was translocated from the cytoplasm to the nucleus after treatment of U937 cells with bufalin. The transcriptional activity of AP-1 was transiently enhanced by the treatment with bufalin and this activation was suppressed by the expression of antisense mRNA for MAPK kinase-1. Both curcumin (1,7-bis[4-hydroxy-3-methoxy-phenyl]-1,6-heptadiene-3,5-dione), an inhibitor of the biosynthesis of AP-1, and the expression of dominant negative c-Jun inhibited the activation of AP-1 and the induction of apoptosis by bufalin. Expression of a constitutively active mutant form of MAPK kinase-1 induced the activation of AP-1 and subsequent apoptosis in U937 cells. These results suggest that the activation of AP-1 via a MAPK cascade that includes JNK is required for the induction of apoptosis by bufalin in U937 cells.
Introduction
We reported previously that bufalin, a bufadienolide in the traditional Chinese medicine chan'su, which is prepared from toad venom, activates the MAPK cascade and induces subsequent apoptosis in human leukemia U937 cells (Watabe et al., 1996) . The MAPK cascade is known to be involved in the early events of signal transduction in response to various agents and stress. The activation of MAPK signaling pathways is a key event in the proliferation and dierentiation of eukaryotic cells. It has been reported that treatments with various reagents, such as epidermal growth factor (EGF), nerve growth factor (NGF), platelet-derived growth factor, ®broblast growth factor, insulin, insulinlike growth factor 1,12-O-tetradecanoylphorbol 13-acetate (TPA), and phorbol 12,13-dibutyrate, all cause the activation of MAPK in quiescent ®broblastic cells (Hoshi et al., 1988) . Moreover, c-Jun N-terminal kinase (JNK), a member of the MAPK family of proteins, has been shown to be involved in apoptosis. JNK can be activated by apoptosis-inducing stimuli, such as u.v. light , g irradiation (Kharbanda et al., 1995) , inhibitors of protein synthesis (Kyriakis et al., 1994) , ceramide (Westwick et al., 1995) , DNAdamaging drugs (van Dam et al., 1995) , chemotherapeutic drugs (Yu et al., 1996) and tumor necrosis factor-a (TNF-a: Sluss et al., 1994) . It has been proposed that the signal that is passed via MAPKs to JNK might be important for the induction of apoptosis (Karin, 1995) .
c-Jun and c-Fos are transcriptional factors with a leucine zipper structure. They form homodimers or heterodimers that bind to DNA in a sequence-speci®c manner and the complex formed by these proteins is called AP-1. AP-1 regulates the activation of transcription of a variety of genes and the activity of AP-1 is regulated by the phosphorylation of MAPKs that include JNK. A requirement for the activation of AP-1 in apoptosis induced by ceramide has been demonstrated (Sawai et al., 1995) . In the present study, we investigated the signal transduction pathway downstream of MAPK in the induction of apoptosis by bufalin in human promonocytic leukemia U937 cells. We found that treatment of U937 cells with bufalin caused activation of AP-1 via the MAPK cascade that included JNK and that such activation was required for the induction of apoptosis in U937 cells.
Results

Activation of JNK1 by bufalin in U937 cells
In a previous study, we found that bufalin caused the marked and persistent activation of MAPK, acting via Ras, in U937 cells (Watabe et al., 1996) . We showed that the anomalous activation of MAPK in U937 cells in response to bufalin was caused by the cooperative interaction of two dierent signaling pathways. To examine the involvement of JNK, one of the MAPK family of proteins, in the apoptotic process induced by bufalin, we measured JNK activity after treatment of U937 cells with bufalin in the absence of fetal calf serum, to circumvent any eects of growth factors in the serum. The dominant form of JNK in U937 cells was JNK1 ( Figure 1a ) with a molecular mass of 46 kDa, as reported previously (Hibi et al., 1993; Sluss et al., 1994) . When U937 cells were treated with 10 treatment and then decreased. As is evident from Figure 1b , JNK activity was increased 3 h after the start of treatment and remained high for 9 h. The activation of JNK by bufalin was slightly weaker than activation by 600 mM sorbitol, which causes osmotic stress and activates JNK. In the absence of bufalin, no activation of JNK was detected (result not shown). In our previous study, both activation of MAPK and induction of apoptosis in response to bufalin were suppressed by the expression of antisense mRNA for MAPK kinase-1 (MAPKK1/MEK1), which is known to activate MAPK (Franklin and Kraft, 1995; Cowley et al., 1994) . We examined whether activation of JNK by bufalin might also be inhibited by the expression of antisense mRNA for MAPKK1. We examined U937 cells that expressed antisense mRNA for MAPKK1 and veri®ed a decrease in the level of MAPKK1 in the cells by Western blotting. Both the basal activity and the activation of JNK by bufalin were suppressed by the expression of antisense mRNA for MAPKK1 (Figure 1c ). This result indicated that MAPKK1, activated by bufalin, was responsible for the activation of JNK1, as well as for MAPK.
Activation of AP-1 via the MAPK cascade in response to bufalin c-Jun and c-Fos, two products of early-response genes, form the transcriptional factor AP-1 and their activities are regulated by phosphorylation by MAPK (Pulverer et al., 1991; Minden et al., 1994) or JNK Minden et al., 1994; Karin, 1995) . To examine the involvement of AP-1 in bufalin-induced apoptosis, we investigated changes in the levels of the c-Jun and cFos proteins in nuclear and cytoplasmic fractions. These proteins are active after translocation from the cytoplasm to the nucleus. Therefore, we performed immunoblotting analysis using speci®c antibodies against c-Jun and c-Fos and nuclear and cytoplasmic fractions of U937 cells that had been treated with bufalin. As shown in Figure 2a , c-Jun protein had been translocated from the cytoplasm to the nucleus 6 h after the start of bufalin treatment, while c-Fos protein was not translocated for at least the ®rst 6 h after the start of treatment. We failed to detect Fra-1 or Fra-2, other members of the family of proteins to which c-Fos belongs, in U937 cells by immunoblotting with appropriate speci®c antibodies (data not shown). These results suggested that bufalin activated a form of AP-1 that consisted of the c-Jun homodimer.
We next examined whether bufalin could change the transcriptional activity of AP-1, using the luciferase assay. As shown in Figure 2b , bufalin induced the transient activation of AP-1 6 h after the start of the treatment. In the absence of bufalin, the transcriptional activity of AP-1 was unchanged by addition of dexamethasone (result not shown). The change in transcriptional activity of AP-1 in U937 cells upon treatment with bufalin was reproducible. To con®rm whether the signals for activation of AP-1 were transmitted through the MAPK cascade that included JNK, we prepared U937 mutant cells that expressed antisense mRNA for MAPKK1. As shown in Figure  2c , the activation of AP-1 6 h after the start of bufalin treatment was suppressed by the expression of antisense mRNA for MAPKK1 in U937 cells. This result indicated that AP-1 was activated in response to bufalin via JNK or MAPK in the MAPK cascade.
Eects of curcumin on the activation of AP-1 and apoptosis in response to bufalin AP-1 is activated during the apoptotic process that is induced by various agents, including ceramide, and it is suppressed upon the inhibition of the synthesis of c-Jun protein by curcumin (1,7-bis[4-hydroxy-3-methoxyphenyl]-1,6-heptadiene-3,5-dione; Huang et al., 1991) . To con®rm the involvement of AP-1 in bufalin-induced apoptosis, we preincubated U937 cells for 1 h with various concentrations of curcumin and then treated them with bufalin for 6 h. As shown in Figure 3a , curcumin suppressed the increase in the level of c-Jun in response to bufalin and it acted in a dose-dependent manner. Activation of AP-1 by bufalin was also inhibited by increasing concentrations of curcumin ( Figure 3b ). Under these conditions, curcumin inhibited the DNA fragmentation induced by bufalin in a dose-dependent manner, as observed in the case of the AP-1 activity (Figure 3c ). Furthermore, increases in the amount of fragmented DNA in response to bufalin, as quanti®ed by a¯uorometric assay with 4',6-diamidine-2-phenylindole dihydrochloride (DAPI), were completely inhibited by curcumin at concentrations above 30 mM (Figure 3d ). It is also noted that treatment of U937 cells with curcumin below 50 mM for 6 h did not aect cell viability or the fragmentation of DNA (results not shown). These results indicated that activation of AP-1 was required for apoptosis of U937 cells in response to bufalin.
The eect of dominant negative c-Jun on bufalin-induced apoptosis
In order to con®rm the role of AP-1 in the induction of apoptosis by bufalin, we prepared a transformant of Figure 4a , while the activation of AP-1 in response to bufalin was observed in U937 cells that had been transfected with the pRC-CMV vector that lacked DcJun (neo), activation was almost completely suppressed by the expression of dominant negative c-Jun in Dc-Jun transformants. This result raised the possibility that the DNA fragmentation induced by bufalin might be inhibited by the expression of dominant negative cJun. Indeed, the ladder pattern of DNA induced by treatment with bufalin was eliminated in the case of Dc-Jun transformants ( Figure 4b ). Furthermore, the amount of fragmented DNA, as quanti®ed by ā uorometric method with DAPI, was markedly reduced by the expression of dominant negative c-Jun (Figure 4c ). These results strongly suggest that apoptosis induced by bufalin in U937 cells can be inhibited by blocking the signal at the level of AP-1.
Activation of AP-1 by the expression of constitutively active MAPKK1
AP-1 is known to be activated by a signal from the MAPK cascade. Therefore, we investigated whether apoptosis would be induced when AP-1 was activated by the expression of constitutively active MAPKK1. In this case, treatment of cells with bufalin should be unnecessary for the activation of AP-1. A constitutively active MAPKK1 protein was prepared by mutating the residues at two key sites of regulatory phosphorylation (Ser218 and Ser222; Zheng and Guan, 1994) between subdomains VII and VIII (Hanks et al., 1988) of MAPKK1 to glutamic amino acid residues (Cowley et al., 1994; Mansour et al., 1994; Gotoh et al., 1994; Brunet et al., 1994; Pages et al., 1994) . We cloned U937 cells that had been stably transfected with a plasmid that encoded a constitutively active MAPKK1 and measured MAPKK1 activity. When constitutively active MAPKK1 was expressed in the U937 transformants in response to dexamethasone in the absence of fetal calf serum, to circumvent any eects of growth factors in the serum, the amount of MAPKK1 increased with increasing duration of treatment with dexamethasone ( Figure 5a ). Thirty-six hours after the start of treatment with dexamethasone, the amount of MAPKK1 had increased ®vefold. We examined whether AP-1 had been activated by the expression of constitutively active MAPKK1. As shown in Figure  5b , we detected activation of AP-1 in transformed U937 cells 36 h after the start of treatment with dexamethasone. The extent of activation of AP-1 was 5.6-fold and was well correlated with the increase in MAPKK1. These results indicated that activation of MAPKK1 in the absence of bufalin, can, by itself, cause an increase in the transcriptional activity of AP-1.
The induction of apoptosis via activation of AP-1 as a result of the expression of constitutively active MAPKK1
To prove the involvement of activation of AP-1 via the MAPK cascade in the induction of apoptosis in U937 cells, we induced the expression of constitutively active MAPKK1 in U937 cells by treatment with dexamethasone in the absence of fetal calf serum and examined the induction of DNA fragmentation. Figure 6a shows that the amount of fragmented DNA, as quanti®ed by a¯uorometric method with DAPI, increased gradually with the time after the start of treatment with dexamethasone. The insert in Figure  6a shows the results of electrophoresis on an agarose gel, of DNA extracted from transformants that had been treated with dexamethasone for 42 h. A ladder of DNA was detected when constitutively active MAPKK1 was expressed in U937 cells after treatment with dexamethasone for 42 h. We also examined whether apoptosis could be induced even in the presence of fetal calf serum when constitutively active MAPKK1 was expressed in U937 cells (Figure 6b) . A slight increase in DNA fragmentation was induced in both wild-type and neo U937 cells in the presence of serum. Treatment with dexamethasone of transfor- mants with constitutively active MAPKK1 caused a signi®cant increase in DNA fragmentation. As controls, stable clones of U937 cells that had been transfected with sense or antisense MAPKK1 plasmids, as reported previously (Watabe et al., 1996) , were treated with dexamethasone but no signi®cant increase in DNA fragmentation was observed as compared with that in wild-type U937 cells. These results suggested that the activation of AP-1 via MAPKK1 in U937 cells represented at least one of the signal transduction pathways that is involved in the induction of apoptosis. 
Discussion
Bufalin induces apoptosis through the abnormal and continuous activation of the MAPK cascade in human leukemia U937 cells (Watabe et al., 1996) . In the present study, we investigated the eect of bufalin on the activity of JNK1, a member of the MAPK family of proteins. We showed that JNK1, as well as MAPK, was activated by bufalin and that the activation of JNK1 was caused, at least, by the activation of MAPKK1/MEK1. JNK is known to be activated by SEK1/MKK4 or JNKK, which is supposed to act just upstream of JNK. Franklin and Kraft (1995) demonstrated that JNK can also be activated by MAPKK1. The present results can, therefore, be interpreted to mean that the signal for activation of JNK by bufalin is transmitted via the activation of MAPKK1. The mechanism of the simultaneous activation of JNK by MAPKK1 is unknown. To date, Jun kinases or JNKs are the only protein kinases known to phosphorylate two amino-terminal residues of c-Jun, Ser63 and Ser73, and to activate transcription by c-Jun dimers (Derjard, 1994; Minden et al., 1994; Karin, 1995) . By contrast, ERK1 and ERK2 phosphorylate residues near the carboxyterminal DNA-binding domain of c-Jun and inhibit binding of DNA (Minden et al., 1994) . It has been demonstrated that the withdrawal of NGF from the culture medium of PC12 pheochromocytoma cells causes activation of JNK and p38, as well as the inhibition of extracellular signal regulated kinases (ERKs) 1 and 2 prior to the induction of apoptosis (Xia et al., 1995) . Xia et al. proposed that a balance between the JNK-p38 and ERK pathways might be important for the induction of apoptosis. One possible explanation for the data obtained in the present study is that a protein phosphatase that dephosphorylates phosphorylated Ser/Thr residues in the carboxyterminal DNA-binding domain of c-Jun might be activated by phosphorylation by MAPKK1 or ERKs. This possibility should be examined in the future.
The activation of AP-1, a transcriptional factor consisting of dimers of members of the Fos and Jun families of proteins, appears to be responsible for the apoptosis that is induced by various agents (Kyriakis et al., 1994; Sawai et al., 1995) . Treatment of U937 cells with bufalin caused the transient activation of AP-1. After 6 h of treatment with bufalin, c-Jun protein was localized in nuclei and c-Fos protein was found only in the cytoplasm. This result suggests that the AP-1 that is activated by bufalin is a homodimer composed of cJun and is able to induce apoptosis in U937 cells. The present results are consistent with the recent report of Bossy-Wetzel et al. (1997) , who demonstrated that the expression of c-Jun-estrogen receptor protein was sucient to induce apoptosis in NIH3T3 ®broblasts. Heterodimers of c-Jun and c-Fos are more stable than dimers formed by c-Jun proteins alone and the DNAbinding activity of the heterodimer is higher than that of the homodimer of c-Jun (Smeal et al., 1989) . At present, it is unknown why bufalin causes translocation of only c-Jun into the nuclei of U937 cells, with subsequent formation of homodimers.
Curcumin is known to inhibit the biosynthesis of cJun and it also inhibits the activation of NF-kB (Singh and Aggarwal, 1995) . We observed in the present study that the amount of c-Jun protein was decreased by treatment with 25 mM curcumin to below the level in untreated U937 cells but that AP-1 activity was not decreased so markedly (compare Figures 3a and b) . These discrepancies can be explained as follows. The translocation of c-Jun from the cytoplasm to the nucleus is important for the activity of AP-1, as shown in Figure 2a and b. The results shown in Figure  3a represent the changes in the total amount of c-Jun and not in the amount of translocated c-Jun.
The induction of apoptosis in U937 cells by bufalin was unaected by addition of cycloheximide at 10 mg/ ml (result not shown). We interpret this result to mean that protein synthesis in U937 cells is not completely inhibited by cycloheximide at this concentration. It was not, however, appropriate to increase the concentration of cycloheximide because, at higher concentrations, cycloheximide itself induces apoptosis in U937 cells. Some proteins needed for the induction of apoptosis might be synthesized even in the presence of cycloheximide under the conditions used in the present experiment.
Since MAPKK1 in U937 cells is activated by bufalin, we attempted to induce apoptosis via the expression of constitutively active MAPKK1 in U937 cells. The mutation of two key sites of regulatory phosphorylation (Ser218 and Ser222; Zheng and Guan, 1994) between subdomains VII and VIII (Hanks et al., 1988) of MAPKK1 to acidic amino acid residues produces a constitutively active MAPKK1 protein (Cowley et al., 1994; Mansour et al., 1994; Gotoh et al., 1994; Brunet et al., 1994; Pages et al., 1994) . We constructed two mutants of MAPKK1, S222E and S218E-S222E, and expressed these mutants in U937 cells. The constitutive expression of active MAPKK1 (S222E) in U937 cells had no eect on the induction of apoptosis (data not shown). However, the expression of constitutively active MAPKK1 (S218E-S222E) in U937 cells activated AP-1 and induced apoptosis. It was reported that the S218E-S222E mutant form of MAPKK was tenfold more active than the S222E mutant form (Mansour et al., 1994) . These data suggest that activation of MAPKK1 above a certain threshold level might induce apoptosis in U937 cells. It has been demonstrated that constitutive activation of MAPKK, which activates MAPK, is necessary and sucient for the induction of dierentiation of PC12 cells (Cowley et al., 1994) and for transformation of NIH3T3 cells (Cowley et al., 1994; Mansour et al., 1994) . However, it has also been shown that constitutive activation of MAPKK inhibits growth of U937 cells (Franklin and Kraft, 1995) . These data suggest that the eects of activation of MAPKK dier among cell lines. If the signal transduction pathways for the induction of apoptosis by bufalin can be clari®ed, we might be able to explain these discrepancies.
Materials and methods
Cell culture
Human promonocytic leukemia, U937 cells were obtained from the Japanese Cancer Resource Bank (Tokyo, Japan). The cells were grown in RPMI-1640 medium supplemented with 10% fetal calf serum at 378C in an atmosphere of 5% CO 2 in air.
Chemicals and radioisotopes
Bufalin and curcumin were purchased from Sigma Chemical Co (St Louis, MO). The luciferase assay system and [g-32 P]ATP (3000 Ci/mmol) were purchased from Promega (Madison, WI) and Amersham International (Amersham, UK), respectively. Geneticin (G418 sulfate) was obtained from Wako Pure Chemical Industries, Ltd (Tokyo, Japan). Antibodies against c-Jun and c-Fos were purchased from Oncogene Science (Uniondale, NY), and antibodies against Fra-1 and Fra-2 were purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, CA).
Treatment with bufalin
Unless otherwise indicated, U937 cells (5610 6 cells) were deprived of serum for 24 h before the addition of bufalin and then they were cultured with 10 78 M bufalin in serum-free RPMI-1640 medium for the indicated times. Cell viability was determined by the trypan blue exclusion test.
Preparation of cell lysates
U937 cells were collected by centrifugation and washed twice with phosphate-buered saline (PBS). The washed cells (5610 6 cells) were lysed with 0.4 ml of lysis buer, which consisted of 10 mM Tris-HCl, pH 7.4, 1 mM EDTA, 0.5 mM ethylene glycolbis(b-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), 0.15 M NaCl, 5 mg/ml aprotinin, 5 mg/ml leupeptin, 5 mg/ml pepstatin A, 5 mg/ml antipain, 0.5 mM phenylmethylsulfonyl¯uoride (PMSF), 50 mM NaF, 2 mM sodium orthovanadate, 10 mM sodium pyrophosphate, and 1% (w/v) Triton X-100. The cell lysate was centrifuged at 15 000 g for 20 min. The supernatant was used for immunoblotting and for measurements of the activities of protein kinases.
Construction of expression vectors that encoded sense and antisense MAPKK1
Construction of sense and antisense MAPKK1 expression vectors were described previously (Watabe et al., 1996) . In brief, cDNA for MAPKK1 was obtained by reverse transcription-PCR using total RNA prepared from U937 cells. Oligonucleotides 5'-AAGGATCCGGGTCCAAAA-TGCCCAAGAA-3' and 5'-AAGGATCCTCCCAAACAC-TTAGACGCCA-3', were used as forward and reverse primers, respectively, for ampli®cation of the gene for MAPKK1. PCR was performed in the presence of 0.5 units of Ex Taq DNA polymerase (Takara Shuzo Co. Ltd., Otsu, Japan) for 40 cycles with a step program (948C, 1 min; 558C, 1 min; 728C, 2 min), which was followed by a 7 min ®nal extension at 728C. The 1.3 kb BamHI fragment encoding the entire human MAPKK1 and the antisense fragment were separately cloned into the XhoI site of pMAM-neo, which contains the dexamethasone-inducible long terminal repeat (LTR) promoter of a mouse mammary tumor virus.
Transfection of U937 cells
Transfections were performed by electroporation with a Gene Pulsor (Bio-Rad, Hercules, CA) as described previously (Watabe et al., 1996) . A pulse was delivered to 0.4 ml of a suspension of U937 cells (4610 6 cells) that contained 10 mg of plasmid DNA. The cells were plated in 96-well microplates (1610 4 cells per well) and cultured in RPMI 1640 medium. After culture for 24 h, geneticin was added at a ®nal concentration of 400 mg/ml and subclones were isolated 2 ± 3 weeks later.
Detection of JNK after SDS-polyacrylamide gel electrophoresis
A separation gel containing 10% (w/v) polyacrylamide, 0.1% (w/v) SDS and 1 mg/ml glutathione S-transferase-cJun (GST-c-Jun; a fusion protein that included GST and residues 1 ± 79 of c-Jun) was prepared as described previously (Watabe et al., 1996) . A cell lysate that contained 40 mg of protein was subjected to electrophoresis on the gel as described previously (Laemmli, 1970) . After electrophoresis, the gel was incubated for 1 h in 50 mM pH 8.0, that contained 20% (v/v) isopropyl alcohol for removal of SDS and then it was incubated for 1 h in buer A, which contained 50 mM TrisHCl (pH 8.0) and 5 mM 2-mercaptoethanol. The proteins in the gel were then denatured for 1 h in buer A supplemented with 6 M guanidine HCl. The denatured proteins were renatured by incubating the gel for 12 h at 48C in buer A that contained 0.05% (w/v) Tween 20 with four changes. The entire gel was then subjected to an assay of kinase activity. After a 30 min preincubation at room temperature in buer B that contained 40 mM 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid (HEPES), pH 7.5, 10 mM MgCl 2 , 2 mM dithiothreitol and 0.1 mM EGTA), the gel was incubated for 1 h in buer B that contained 20 mM [g-32 P]ATP (25 mCi) at 308C. The gel was washed extensively with a solution of 5% (w/v) trichloroacetic acid plus 1% (w/v) sodium pyrophosphate and then it was dried and subjected to autoradiography at 7808C on X-ray ®lm (X-Omat AR; Kodak, Rochester, NY) with an intensifying screen. The incorporation of 32 P into proteins was quanti®ed with a Bioimager Analyzer (BAS 2000; Fuji Photo Film Co. Ltd., Tokyo, Japan).
Determination of JNK activity
A fusion vector for GST-c-Jun(1 ± 79) was constructed by cloning a fragment of the gene for c-jun gene fragment (encoding amino acids 1 ± 79) into the pGEX-3X vector. The fusion protein was expressed in E. coli Px21 and puri®ed with glutathione-Sepharose 4B (Pharmacia Biotech, Uppsala, Sweden). JNK activity was determined by incubation of a whole-cell extract (0.5 mg) with 10 mg of GST-c-Jun(1 ± 79) conjugated to glutathione-agarose beads (Hibi et al., 1993) for 1 h at 48C. The agarose beads were pelleted by brief microcentrifugation and the bound protein complexes were washed ®ve times with HEPES binding buer (20 mM HEPES, pH 8.0, 20 mM MgCl 2 , 0.1 mM EDTA, 50 mM NaCl, 0.05% Triton X-100). The ®nal wash was performed with kinase buer (20 mM HEPES, pH 8.0, 20 mM MgCl 2 , 20 mM b-glycerophosphate, 0.1 mM sodium orthovanadate, 2 mM dithiothreitol). The kinase reaction was initiated by addition of 30 ml of kinase buer plus 20 mM [g-32 P]ATP (0.5 mCi/assay) to the pelleted beads, with incubation for 10 min at 308C. The reaction was terminated by addition of 1 ml of ice-cold HEPES binding buer. The beads were pelleted, resuspended in sample buer for SDS ± PAGE and boiled for 5 min. Proteins were resolved by electrophoresis on an SDS-polyacrylamide (10%) gel with subsequent autoradiography.
Immunoblotting
Cell lysates containing 20 mg of protein were subjected to SDS ± PAGE and the proteins were then transferred to a polyvinylidene di¯uoride membrane with a wet-blotting apparatus operated at a constant voltage of 0.5 V/cm 2 for 3.5 h in an ice-cold bath. The membrane was washed with 20 mM Tris-HCl buer, pH 7.4, that contained 0.15 M NaCl (TBS) and was then blocked with 3% (w/v) bovine serum albumin in TBS for 30 min at room temperature. The blocked membrane was subsequently probed for 1 h at room temperature with antibodies against Bcl-2, which had been diluted 1 : 1000 in TBS that contained 0.1% (w/v) bovine serum albumin. After washing with TBS that contained 0.1% (w/v) Tween 20 (TTBS), the membrane was incubated for 1 h at room temperature with horseradish peroxidase-conjugated goat antibodies against mouse IgG (heavy and light chains; American Qualex, Lamirada, CA), which had been diluted 1 : 2000 in TBS that contained 0.1% (w/v) bovine serum albumin. After washing with TTBS, bands of proteins on the membrane were visualized with Renaissance R , an enhanced luminol reagent (DuPont NEN, Boston, MA).
Determination of luciferase activity to monitor the activation of AP-1
The promoter region (7517 to +63) of the gene for collagenase that contained a TPA response element was generated by PCR. Human genomic DNA was isolated from U937 cells and dissolved in PCR buer that contained 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 1 mM MgCl 2 , 50 pmol of the forward primer 5'-ACTCGAGGG-TACCAGGCAGCTTAACAA-3' and 50 pmol of the reverse primer 5'-AAGATCTCCTTTGTCTTCTTTCT-CAGTG-3'. PCR was performed in the presence of 0.5 unit of Ex Taq DNA polymerase (Takara Shuzo Co. Ltd.) for 40 cycles with a step program (948C, 1 min; 558C, 1 min; 728C, 2 min), which was followed by a 7 min ®nal extension at 728C. The 0.5 kb product of PCR was cloned into the XhoI and BglII sites of a Pica gene basic vector (Toyo Inki Co., Tokyo, Japan). U937 cells were transfected with this vector using lipofectin (Life Technologies, Inc., Tokyo, Japan). The transfected U937 cells were treated with 10 78 M bufalin. The cells were collected, washed with PBS and lysed in lysis buer (Promega). The lysate was centrifuged at 15 000 g for 5 min and the supernatant was then subjected to the assay of luciferase activity using an assay kit (Promega) according to the manufacturer's manual.
Analysis of DNA fragmentation by agarose gel electrophoresis
Cells were collected by centrifugation and washed with PBS. The washed cells were lysed with a solution of 10 mM Tris-HCl (pH 8.0), 10 mM EDTA, 0.5% (w/v) SDS and 0.1% (w/v) RNase A, and the lysate was incubated ®rst for 60 min at 508C and then for an additional 60 min at 508C with 1 mg/ml proteinase K. Finally, it was subjected to electrophoresis in a 1% (w/v) agarose gel in 40 mM Trisacetate (pH 7.5) that contained 1 mM EDTA for 60 min at 50 V. After electrophoresis, DNA was visualized by staining with ethidium bromide.
Quanti®cation of the extent of DNA fragmentation
The cells were suspended in a solution of 5 mM Tris-HCl (pH 7.4) 1 mM EDTA, 0.5% (w/v) Triton X-100 and left for 20 min on ice. The suspension was centrifuged at 27 000 g for 20 min and the fragmented DNA was recovered from the supernatant. The pellet remaining in the centrifugation tube was sonicated for 1 min at 45 W in a sonicator (Tomy Seiko Co. Ltd., Tokyo, Japan). The amounts of DNA in the supernatant and pellete were determined by a¯uorometric method with DAPI. The intensity of¯uorescence was measured at 454 nm with excitation at 362 nm. The extent of DNA fragmentation, as a percentage, was de®ned as the ratio of the amount of fragmented DNA to the total amount of DNA multiplied by 100.
Preparation of dominant negative c-Jun and construction of an expression vector
Since the gene for c-Jun is an intronless gene, full-length cDNA for c-Jun was generated by PCR with human genomic DNA as template. Human genomic DNA was isolated from U937 cells and dissolved in PCR buer that contained 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 1 mM MgCl 2 , 50 pmol of the forward primer 5'-CTCGGACGG-GAGGAACG-3' and 50 pmol of reverse primer 5'-CAGAAAGTCATGAACC-3'. PCR was performed under the same conditions as described above. To obtain cDNA for dominant negative c-Jun, PCR was repeated with the forward primer 5'-AAAGCTTATGAGCCAGAACACG-CTGCCC-3' and the reverse primer 5'-ATCTA-GACTCTCTTCAAAATGTTTGCAAC-3' and the 1 kb product of PCR as template. The 0.6 kb product of PCR was cloned into the HindIII and XbaI sites of the pRC-CMV expression vector.
In vitro mutagenesis and construction of a plasmid that encoded constitutively active MAPKK1
A BamHI fragment of cDNA for human MAPKK1 was subcloned into M13mp18. Mutation of Ser218 to Glu and Ser222 to Glu in human MAPKK1 was performed as described previously (Kunkel et al., 1987) with mutagenic primers 5'-ACTCCATGGCCAACGAGTTCGTGGGCA-CAAG-3' and 5'-GGCAGCTCATCGACGAGATGGC-CAACGAGTTC-3' to yield SENSE-MAPKK1. Phosphorylation of Ser218 and Ser222 results in activation of human MAPKK1 and the replacement of these residues by glutamic acid residues renders MAPKK constitutively active. The entire sequence of MAPKK1 was analysed to ensure that only the desired mutations had been introduced. The 1.3 kb BamHI fragment that encoded the constitutively active human MAPKK1 was cloned into the NheI site of pMAM-neo, which is an expression plasmid that is inducible by dexamethasone. U937 cells were transfected with the plasmid that encoded constitutively active MAPKK1 by electroporation, as described above.
Abbreviations DAPI, 4',6-diamidine-2-phenylindole dihydrochloride; EGF, epidermal growth factor; EGTA, ethylene glycolbis(b-aminoethyl ether)-N,N,N',N'-tetraacetic acid; ERK, extracellular signal-regulated kinase; GST, glutathione Stransferase; HEPES, 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid; JNK, c-Jun N-terminal protein kinase; MAPK, mitogen-activated protein kinase; NGF, nerve growth factor; PCR, polymerase chain reaction; PMSF, phenylmethylsulfonyl¯uoride; TFA, tri¯uoroacetic acid; TNF-a, tumor necrosis factor-a.
